Producers of original drugs on the Romanian market invested EUR 77.1 million in 2014 in Romania, most of this money going into research& development in medicine and projects developed to the benefit of the patient and medical community, according to the results of a survey carried out by PwC Romania for the Romanian Association of International Drug Producers (ARPIM)
“In 2014, out of the total EUR 77.1 million, EUR 30.8 million were allocated to carrying out clinical trials in therapeutic areas such as hematology, oncology, cardiology, infectious diseases and neurology,” according to Călin Gălăşeanu, president ARPIM.
Also, 37.5 million were invested into programs of prevention and medical education for patient associations and the community of medical professionals in Romania. In 2015, ARPIM member companies supported 110 prevention, testing and monitoring campaigns that reached over 200,000 patients, according to the survey.
“The Romanian healthcare system is in deep crisis and the needs of patient communities and those of the medical community are not always met in the answer of the authorities. There are numerous prevention and information campaigns from patient associations, who are supporting the population’s level of information on diseases and prevention factors in which ARPIM member companies invested in trying to support the Romanian health system,” said Galaseanu.
Apart from the investment into medical research, the impact of the industry at economic and social level in 2014 was defined also by:
- direct and indirect contributions of EUR 911 million to the country’s GDP
- direct contributions of EUR 313 million in taxes, of which EUR 240 million from the clawback tax
- the creation of 16,700 work places both directly and indirectly within companies that are supplying goods and services to original drug producers
The survey called The Impact of the Innovating Drug Manufacturing Industry was carried out based on data supplied in 2015 by 80 percent of companies that are ARPIM members.